Find trials
Search tips

Transcriptomic Changes Before and After Anti-tnf Therapy Utilizing Optimum Therapeutic Drug Levels

Overview

About this study

The purpose of this study is to evaluate infliximab drug levels and anti-infliximab antibody levels in HiSCR50/IHS4 responders versus non-responders at week 18. Investigate gene expression patterns in patients with HiSCR50/IHS4 high response versus nonresponse before treatment and at week 18. Identify biomarkers and immune cells associated with treatment response to infliximab.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • HS patients who have the most severe disease, multiple treatment failures, and frequent hospitalizations.
  • African American patients are disproportionately affected by severe HS,4 and the study is designed to ensure their inclusion in proportions reflective of HS demographics.

Exclusion Criteria: 

  • Less than 18 years of age.
  • Greater than 75 years of age

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 1/27/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Stella Chen, M.D.

Contact us for the latest status

Contact information:

Samantha Devlin C.M.A.

(480) 342-2906

Cosby.Samantha@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20591093

Mayo Clinic Footer